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ABSTRACT  
Tobacco smoking was examined as a risk for dementia and neuropathological burden in 
531 initially cognitively normal older adults followed longitudinally at the University of 
Kentucky’s Alzheimer’s Disease Center. The cohort was followed for an average of 11.5 
years; 111 (20.9%) participants were diagnosed with dementia, while 242 (45.6%) died 
without dementia. At baseline, 49 (9.2%) participants reported current smoking (median 
pack-years=47.3) and 231 (43.5%) former smoking (median pack-years=24.5). The  
hazard ratio (HR) for dementia for former smokers vs. never smokers based on the Cox 
model was 1.64 (95% CI: 1.09, 2.46), while the HR for current smokers vs. never 
smokers was 1.20 (0.50, 2.87). However, the Fine-Gray model, which accounts for the 
competing risk of death without dementia, yielded a subdistribution hazard ratio 
(sHR)=1.21 (0.81, 1.80) for former and 0.70 (0.30, 1.64) for current smokers. In 
contrast, current smoking increased incidence of death without dementia (sHR=2.38; 
1.52, 3.72). All analyses were adjusted for baseline age, education, sex, diabetes, head 
injury, hypertension, overweight, APOE-ε4, family history of dementia, and use of 
hormone replacement therapy. Once adjusted for the competing risk of death without 
dementia, smoking was not associated with incident dementia. This finding was 
supported by neuropathology on 302 of the participants. 
 
3 
 
 
 
 
INTRODUCTION 
Tobacco smoking has been described as a modifiable risk factor for dementia.  This 
statement is supported by several meta-analyses of observational studies showing that 
the relative risk associated with smoking ranges from 1.16-1.27 for dementia and 
ranges from 1.45-1.79 for Alzheimer’s disease (AD) [1-3]. Public policy analyses based 
on these data estimate that nearly 14% (4.7 million) of AD cases worldwide and 11% 
(575,500 cases) in the US are attributable to smoking [4]. As a result, smoking 
cessation has become an integral part of several dementia prevention programs [5-7]. 
The purpose of this manuscript is to examine the risk of dementia associated with 
lifetime smoking in a longitudinal cohort of 531 initially cognitively intact individuals with 
a high prevalence of current and former smoking. This group represents the initial 
waves of participants recruited to the Biologically Resilient Adults in Neurological 
Studies (BRAiNS) cohort, previously described in detail [8]. These individuals are well 
characterized with annual cognitive assessments and a high autopsy rate upon death.  
 A standard Cox model examines smoking history as a risk for dementia after 
adjustment for known confounders while treating death without a dementia as a right 
censored event. This analysis is then compared to a similar statistical analysis that 
treats these dementia-free deaths as a competing event. Neuropathology findings on a 
large proportion of the subjects in the cohort and a pilot study on cause of death are 
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used to inform these two approaches to the data analysis. Analyses of 
neuropathological data are critical when evaluating risk factors for dementia, since 
analysis of clinical diagnosis alone can lead to substantially biased conclusions, as has 
been demonstrated with analyses of diabetes and AD risk [9]. 
MATERIALS AND METHODS 
Subject population 
BRAiNS is a longitudinal cohort followed at the University of Kentucky Alzheimer’s 
Disease Center (UK ADC) [8]. Participants are at least 60 years old, community-
dwelling, and relatively healthy at baseline (e.g., history of stroke is an exclusion 
criterion, but history of diabetes or hypertension is not). Participants are followed 
annually with detailed cognitive and neurological assessments, and they donate their 
brains for autopsy upon death. Full details on the cognitive assessments have been 
previously published [8]. Diagnosis of dementia was determined by DMS-IV criteria [10] 
and diagnosis of Mild Cognitive Impairment (MCI) was determined by the Petersen 
criteria [11]. Participants in the current study were enrolled between 1989 and 2003; this 
window was selected to allow sufficient time to observe the endpoints of interest: death 
prior to dementia, and dementia. Additionally, included participants had to have at least 
two assessments and have APOE genotype available. The University of Kentucky 
Institutional Review Board approved all research procedures, and each participant 
provided informed consent for participation in the cohort and brain autopsy. 
Smoking exposure 
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Participants completed a structured interview at baseline that included the questions 
“Do you smoke? If yes, how many cigarettes per day and for how many years? If you do 
not smoke now, did you ever smoke? If yes, when did you stop, how many cigarettes 
per day, and for how many years?” Participants were also asked about smoking pipes 
and cigars, with similar data collected on years smoked and average daily exposure. 
Participant responses were recoded into categories of smoking behavior (never, former, 
current), which was our primary exposure variable. Pack-years of smoking were also 
estimated from the responses, including data on pipes and cigars. Cigarette, pipe, and 
cigar smoking were converted to pack-years based on the standard conversion factors: 
1 pack = 20 cigarettes, 1 pipe = 2.5 cigarettes, and 1 cigar = 4 cigarettes. Pack-year 
data were used in sensitivity analyses. Since smoking information was not updated 
regularly between 1989 and 2005, it was not possible to obtain end-of-follow-up 
smoking data for many participants. Thus, smoking exposure was fixed at baseline. 
Covariates 
Potential confounders for the association between smoking and dementia, as well as 
smoking and death, were included in the analyses. Covariates were fixed at baseline 
and included age in years and dummy indicators for APOE-ε4 carrier status (any 4 vs. 
no 4 allele), female sex, low education (i.e., less than a high school education), Type 2 
diabetes, head injury, hypertension, overweight (body mass index > 25), family history 
of dementia (defined as a first degree relative), and use of hormone replacement 
therapy. Medical history information was self-reported by the participant during the 
structured baseline interview.  
Neuropathology measures 
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Neuropathological evaluations were performed blind to clinical data (i.e., cognitive 
status and exposure status) as described previously [12]. Alzheimer’s disease 
neuropathologic changes (ADNC), diffuse (neocortical) Lewy body disease, 
hippocampal sclerosis of aging (HS-Aging) pathologies were as described using criteria 
as defined in consensus papers [13-16].  Additional cerebrovascular pathology 
measures included indicators for brain infarction, as well as ordinal ratings of 
atherosclerosis, cerebral amyloid angiopathy, and arteriolosclerosis [17]. Since we did 
not have Thal amyloid phases for all cases, a modified ADNC rating was derived as 
described previously [9]. For analysis, ordinal neuropathology variables were 
dichotomized as follows: ADNC as Intermediate/High AD vs. No/Low AD; Braak stage 
as V/VI vs. 0-IV; atherosclerosis as all vessels < 50% occluded vs. all vessels > 50%; 
diffuse plaques, neuritic plaques, arteriolosclerosis, and cerebral amyloid angiopathy as 
Moderate/Severe vs. None/Mild.  
Cause of death 
Primary cause of death was recorded by the neuropathologist when provided by the 
attending medical personnel or next of kin. These text descriptions were then classified 
into the following 13 mutually exclusive categories: accidental, cancer, dementia, 
embolism, failure to thrive, heart disease, infection, liver failure, pneumonia, chronic 
respiratory, renal disease, stroke, and other. Geriatric “failure to thrive” is a term 
adapted from the pediatric literature and refers to significant weight loss at the end of 
life due to cessation of eating and drinking. Authors RJK and ELA manually coded the 
causes of death, and both were blinded to cognitive status and all other data collected 
on the deceased.  
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Statistical analysis 
Descriptive statistics were computed using means, standard deviations or medians and 
inter-quartile range (IQR). Proportions were compared using chi-square statistics. 
Survival time was defined as the length of time from baseline until the first event of 
interest, either a dementia diagnosis or death without a dementia diagnosis. The age at 
the first diagnosis of dementia was taken to be the average of the age at which the first 
diagnosis of dementia occurred and the age at the prior visit, to reflect our uncertainty 
about the true onset age. Otherwise, survival time was calculated as time from baseline 
to last follow-up. We did not exclude dementia diagnoses that occurred early during 
follow-up from the analysis because of the clear temporal sequencing between initiation 
of smoking exposure and onset of dementia. In other words, reverse causality, where 
preclinical or prodromal neuropathological disease “causes” the exposure (e.g., 
depression, anxiety, or insomnia) is unlikely to play a role here. Effect measure 
modification by age and sex were evaluated using cross-product interaction terms, while 
effect measure modification by APOE-ε4 and education status were evaluated using 
stratification due to low numbers of participants with APOE-ε4 and low education within 
some smoking groups. Since just 5/531 participants reported non-White race, race was 
not further considered in the analysis.   
The Cox model treats all right censored nonevents as uninformative. Thus, the Cox 
model handles participants still at risk for dementia at their last follow-up (i.e., 
administrative censoring) and those who died before dementia (i.e., informative 
censoring) the same way. Since death prior to dementia fundamentally alters the 
probability of observing dementia, this event should not be treated as uninformative. 
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Thus, we refit the model to adjust the hazard of dementia for the competing risk of death 
without dementia using the subdistribution hazard model developed by Fine and Gray 
[18].  As a sensitivity analysis, we redefined the cognitive event to include first diagnosis 
of either MCI or dementia and refit the models. Age at diagnosis of MCI was calculated 
as described above for age at diagnosis of dementia; here, the competing risk of death 
was defined as occurring prior to both MCI and dementia. All computations were 
performed using PROC PHREG in SAS 9.4® [19]. Cumulative incidence curves with 
95% confidence limits were generated using the ‘baseline’ statement in this procedure. 
Analyses of neuropathological features were performed using logistic regression, where 
the log-odds of the more severe pathology were estimated. Smoking exposure was 
treated as binary (ever vs. never), and these analyses were adjusted for age at death, 
sex, and APOE-ε4. As a sensitivity analysis, we further adjusted these models for 
hypertension and diabetes. As additional sensitivity analyses, we replaced the smoking 
indicator variable with baseline pack-years of exposure and re-fit the models. As above, 
potential effect measure modification by age and sex was assessed via cross-product 
interaction terms. Since longitudinal medical history was unavailable for approximately 
1/3 of the autopsied participants, hypertension and diabetes were fixed at baseline. 
For the cause of death analysis, we ranked the causes by frequency and examined 
associations with smoking, dementia, and neuropathology using proportions and 
unadjusted odds ratios. Adjustment was not performed for cause of death analyses, 
which we considered exploratory due to the large portion of missing data and likely 
biases in reporting.  
RESULTS    
9 
 
Mean age at enrollment was 73.2±7.4 years; participants were majority female (63.1%) 
and highly educated (mean 16.0±2.4 years) (Table 1). A large percentage (40.3%) 
declared a positive family history of dementia and other risk factors for dementia 
including diabetes (8.3%), hypertension (53.1%), and head injury (15.4%). At least one 
APOE-ε4 allele was present in 30.3% of participants.  
Smoking exposure was common: 49 (9.2%) participants reported current smoking at 
baseline (median pack-years=47.3), while 231 participants reported former smoking 
(median pack-years=24.5) (Table 1). Former smokers were significantly older than 
current smokers, and were significantly less likely to be female; never smokers were 
significantly more likely to report a family history of dementia. Smoking groups were 
statistically comparable on the remaining characteristics in Table 1. 
Median survival time was lengthy at 11.4 years (IQR 7.4-14.0). For the subset of 178 
participants who did not experience either incident dementia or death, median survival 
time was even longer at 14.3 years (IQR 10.7-16.7). Mean age at the end of follow-up 
was 84.7 ± 7.3 years; mean age for the subset of 111 participants who transitioned to 
clinical dementia was 85.5 ± 7.0 years, and for the subset of participants who died 
without dementia it was 86.3 ± 7.5 years. MCI was diagnosed in 55/178 (30.9%) 
participants who did not die before dementia or develop dementia. Of these, 12/55 
(21.8%) died with a diagnosis of MCI. 
Survival analysis 
The Cox model indicated smoking was a risk for incident dementia with adjusted 
HR=1.64 for former smokers vs. never smokers (95% CI: 1.09, 2.46); for current 
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smokers, adjusted HR=1.20 (0.50, 2.87).  Having at least 10 pack-years of smoking 
history (n=215) vs never smoking (n=251) was also associated with dementia, with an 
adjusted HR=1.65 (1.08, 2.53). Less than 10 pack-years (n=65) vs. never smoking 
yielded an adjusted HR=1.39 (0.76, 2.58). The cut-point 10 pack-years was chosen 
since it was the lower quartile of exposure in the former smoker category. There was no 
effect measure modification by age or sex for any of these analyses. 
However, once adjusted for the competing risk of death without dementia, current 
smoking was no longer a significant risk for dementia. The adjusted subdistribution 
hazard ratio (sHR) was 1.21 (95% CI: 0.81, 1.80) for former and 0.70 (0.30, 1.64) for 
current smokers. The adjusted sHR for at least 10 pack-years of exposure was 1.14 
(0.76, 1.71). In contrast, baseline current smoking increased the incidence of death 
without dementia (sHR = 2.38; 1.52, 3.72). These results are illustrated in the 
cumulative incidence curves of Figure 1.  
While there was no observed effect measure modification by age, the association 
between smoking status and death without dementia was modified by sex. For former 
smokers vs. never smokers, the sHRfor men was 1.34 (0.83, 2.01) and 0.97 (0.65, 1.44) 
for women. For men, current vs. never smoking yielded sHR=1.16 (0.52, 2.58), while for 
women the sHR=4.13 (2.56, 6.67). For participants with high education, the sHR for 
death for current vs. never smoking was 2.00 (1.20, 3.34) and was 1.21 (1.08, 1.99) for 
former vs. never smoking. For participants with low education, the sHR for death for 
current vs. never smoking was 4.40 (1.36, 14.23) and 0.80 (0.32, 1.88) for former vs. 
never smoking. For participants with high education, sHR for dementia for current vs. 
never smoking was 0.84 (0.36, 1.99) and was 1.13 (0.74, 1.72) for former vs. never 
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smoking. Due to low numbers, hazard ratios for dementia were not estimable in the low 
education stratum. For participants with at least one APOE-ε4 allele, the sHR for death 
for current vs. never smoking was 0.92 (0.28, 2.97) and 1.65 (0.96, 2.85) for former vs. 
never smoking. For participants no ε4 allele, the sHR for death was 3.61 (2.38, 5.49) for 
current vs. never and 1.03 (0.74, 1.44) for former vs. never smoking. For dementia, the 
sHR for current vs. never smoking was 1.40 (0.45, 4.31) and 0.99 (0.51, 1.92) for former 
vs. never smoking for ε4 allele carriers, and 0.36 (0.08, 1.55) for current vs. never and 
1.37 (0.82, 2.30) for former vs. never smokers.  Overall, we note that none of the effect 
measure modification analyses revealed significant associations between either current 
or former smoking and incident dementia within strata of the potential modifiers. 
However, some factors significantly increased the incidence of death before dementia 
for baseline current smokers: female sex, no APOE-ε4 allele, and low educational 
attainment.  
When first diagnosis of either MCI or dementia was used as the cognitive event, death 
was considered a competing event only if it occurred prior to the first diagnosis of any 
cognitive impairment. This yielded 178/531 (33.5%) participants with an incident 
diagnosis of cognitive impairment, and 230/531 (43.3%) who died before cognitive 
impairment. In this analysis, the adjusted HR derived from the Cox model for former 
smokers vs. never smokers was 1.33 (95% CI: 0.96, 1.83) and 0.80 (0.39, 1.61) for 
current smokers vs. never smokers. In the competing risk analysis, the subdistribution 
HR for former smokers vs. never smokers was 0.97 (0.70, 1.34) and 0.51 (0.26, 0.99) 
for current smokers vs. never smokers. As in the dementia-only analysis, the Fine-Gray 
results showed that the apparent protective effect of smoking among current smokers is 
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explained by an increased incidence of mortality vs. never smokers (sHR=2.52; 1.63, 
3.89). The incidence of mortality was not significantly increased among former smokers 
vs. never smokers (sHR=1.16; 0.87, 1.56). 
Autopsy data 
Of the 531 participants in the study, 350 died and 302 came to autopsy (86.3%). 
Average age at death was 88.6±7.1 years among autopsied never smokers and 
86.2±7.5 years among ever smokers. Neuropathological features were cross-tabulated 
against smoking history (Table 3). Compared to never smokers, ever smokers were less 
likely to have higher levels of any of the neuropathological features studied, with the 
exception of lacunar infarcts. Adjustment for age at death, sex, and APOE-ε4 did not 
alter the direction of these associations, and the severity of atherosclerosis, presence of 
pale infarcts, and presence of macro-infarcts were significantly lower among smokers 
(Table 3). Further adjustment for diabetes and hypertension did not appreciably change 
the results. There was no evidence of effect measure modification by age or sex for any 
of the analyses. Analyses based on pack-year data were consistent with the 
dichotomized smoking variable in both direction of the association and lack of statistical 
significance. 
Cause of death                                                                                
The cause of death was reported for 193/302 (63.9%) autopsied cases. Cause of death 
was reported for 111/161 (68.9%) smokers and 82/141 (58.2%) never smokers. The top 
four causes of death were heart disease (n=47), cancer (n=48), pneumonia (n=23), and 
stroke (n=21), representing 72.0% of the reported causes of death. Reported deaths in 
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all four categories tended to occur in non-demented participants, with 6/47 (12.8%) 
heart disease, 7/48 (14.6%) cancer, 8/23 (34.8%) pneumonia, and 8/21 (38.1%) stroke 
deaths in each group diagnosed with dementia prior to death. For cases with unreported 
cause of death, 40/109 (36.7%) were diagnosed with dementia prior to death. Smoking 
history, however, was much more common among these deaths: 29/47 (61.7%) heart 
disease, 32/48 (66.7%) cancer, 16/23 (69.6%) pneumonia, and 8/21 (38.1%) stroke 
deaths were ever smokers. We note that the percent of ever smokers among all cases 
with known cause of death is 57.5% (111/193). For cases with unreported cause of 
death, 50/109 (45.9%) were ever smokers. Among cases with reported cause of death, 
85/111 (76.6%) with a smoking history died of the top four causes, compared to 54/82 
(65.9%) with no smoking history: OR = 1.70 (95% CI: 0.90, 3.19).  
DISCUSSION 
Here we provide evidence that the reported association between smoking and risk of 
dementia may be due to analytical methods that do not consider the competing risk of 
death without dementia. The Cox proportional hazards model, which is widely used in 
epidemiological research, treats competing events as uninformative censoring. 
However, when we treated these deaths as a competing risk in the analysis, smoking 
was no longer associated with dementia. The data used to illustrate this point were 
drawn from the UK ADC BRAiNS cohort, which provided a large sample of initially 
cognitively normal older adults (age 60+) followed for many years, with ample exposure 
to tobacco smoking (52.7% of participants had a smoking history). Most importantly, we 
had sufficient numbers of events (111 incident dementia diagnoses vs. 242 deaths 
without dementia) to make the case that smoking was a risk for earlier death but not for 
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dementia. Large autopsy numbers (n=302) were used to support this finding since 
pathology shows that a smoking history was associated with a lower probability of AD or 
other neuropathology at death. These results were further supported by our analysis of 
causes of death, which showed that smokers tended to die of causes of death that were 
not associated with dementia. The top two reported causes of death (heart disease and 
cancer) were dominated by smokers (64.2% of deaths due to these causes were among 
smokers). Where cause of death was reported, consistent with the smoking literature 
[20], heart disease and cancer accounted for 56.0% of deaths among those who died 
without dementia but only 27.7% of those who died with dementia.  
The conclusion that smoking did not increase the incidence of dementia, or cognitive 
impairment more generally, conflicts with the results of prior studies [1-3]. However, 
these analyses all relied on the standard Cox model to determine the association 
between smoking and dementia. Statistically, these studies are examining the marginal 
distribution of survival (i.e., time to dementia). In the case where there is heavy 
competition from another event, this can be misleading. An alternative is to examine the 
subdistribution of survival time to dementia, which adjusts for the presence of competing 
risks. This relies on estimating the cumulative incidence function, which accounts for 
competing risks. Adjustment for other covariates is made using a proportional hazards 
version of the cumulative incidence function due to Fine and Gray [19]. This approach is 
well known and has been adopted in other fields of medicine including cancer, 
cardiovascular disease, and gerontology [21-23]. Surprisingly, it is not the standard 
approach in the field of dementia research, where the competing risk of death is ever 
present. 
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Another alternative approach to adjusting for competing risks is to adopt a multistate 
model in which participants flow through different health states such as the pre-
dementia states of mild cognitive impairment (MCI) and competing risk states such as 
participant withdrawal and death without a dementia. This approach has been 
successfully used to study self-reported head injury and MCI [24-25]. The Markov chain 
approach works well if the cognitive assessments are equally spaced but can introduce 
some bias if not [(26]. Although the model becomes more complex, the unequally 
spaced intervals can be handled using a semi-Markov process, which also adjusts for 
competing risks [27].  
For neurodegenerative diseases, it is critical to validate clinical findings with 
neuropathological findings due to the imperfect correlation between clinical diagnoses of 
dementia and neuropathology [9,28].  Our findings do not support a link between 
smoking and AD pathology. This is consistent with several prior neuropathological 
studies of smoking and AD pathology [29] but not all [30].  
Somewhat surprisingly, smoking was generally not associated with increased 
cerebrovascular pathology, other than lacunar infarcts. However, the association with 
lacunes was not statistically significant. In addition, other neuropathologies also 
appeared to be less prevalent among those with a positive smoking history. This could 
be due in part to the smokers dying an average of two years sooner than never 
smokers. Other explanations may include chemotherapy treatments received by 
smokers who developed cancer [31] or a healthy survivor effect. The cohort studied 
here, which is community rather than population-based, comprises highly educated 
participants who had already survived to at least age 60 in good health, and in many 
16 
 
cases survived into their late 80s and beyond. This may mean that our participants were 
better able to resist deleterious effects of smoking on the brain than other populations 
given similar levels of exposure. 
Despite its many strengths this study has some limitations. Smoking was by self-report 
and fixed at study entry. Therefore, we do not know the full extent of exposure to 
tobacco smoke among those actively smoking at enrollment, or former smokers who 
may have reinitiated smoking. However, even at baseline the current smokers had 
much higher median pack-years of exposure, and it is unlikely that these additional data 
would have changed our results. We also did not have data on secondhand smoke 
exposure, or data on diet and physical activity. While the autopsy rate was high 
(86.3%), the missing autopsies may introduce bias. The recording of cause of death 
may also be vulnerable to selection and information bias. This may limit the 
generalizability of the results, so further studies on the implications of ignoring the 
competing risk of death before dementia on risk factor identification are needed using 
population-based data.    
In conclusion, this study shows that when adjusted for the competing risk of death 
without dementia, smoking was not associated with increased risk of dementia or AD 
pathology in a cohort with high prevalence of lifetime smoking. This may have 
implications for the current focus on smoking cessation as a modifiable risk for 
dementia. We emphasize that this is not to say that efforts invested in smoking 
cessation are misguided or unimportant, since smoking clearly increases the risk of 
multiple other chronic diseases, including cardiovascular disease and cancer, as well as 
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earlier mortality. However, smoking cessation efforts focused on preventing dementia 
may not provide the expected benefit at the population level [4].  
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Table 1: Characteristics of the BRAiNS cohort (enrolled 1989–2003) by baseline smoking status  
Characteristic*  All 
Participants 
(N=531) 
Never 
Smokers 
(N=251) 
Former 
Smokers 
(N=231) 
Current 
Smokers 
(N=49) 
Baseline age, years 73.2±7.4  72.9±9.2 74.1±7.5 71.1±7.1 
Education, years  16.0±2.4  16.1±2.3 16.0±2.5 15.3±2.2 
Low education (< 12 years) 62 (11.7) 29 (11.6) 25 (10.8) 8 (16.3) 
Female sex 335 (63.1)  183 (72.9) 122 (52.8) 30 (61.2) 
APOE-ε4 carrier  161 (30.3)  79 (31.5) 70 (30.3) 12 (24.5) 
Family history of dementia  214 (40.3)  116 (46.2) 81 (35.1) 17 (34.7) 
Type 2 diabetes  44 (8.3) 23 (9.2) 19 (8.2) 2 (4.1) 
Body Mass Index > 25  227 (42.8)  110 (43.8) 97 (42.0) 20 (40.8) 
Hypertension 282 (53.1) 135 (53.8) 119 (51.5) 28 (57.1) 
Head Injury 82 (15.4)  34 (13.5) 41 (17.7) 7 (14.3) 
Hormone replacement 
therapy (% all subjects) 
99 (18.6) 57 (22.7) 32 (13.9) 
 
10 (20.4) 
Smoking pack-years 2 (0-30) 0 24.5 (10-42) 47.3 (25.6-62.5) 
Incident dementia diagnosis 111 (20.9) 54 (21.5) 51 (22.1) 6 (12.2) 
Death without dementia 242 (45.6) 103 (41.0) 111 (48.1) 28 (57.1) 
*All results presented are mean±SD or n (%), with the exception of pack-years, which are 
median (IQR).  
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Table 2: Adjusted hazard ratios and subdistribution hazard ratios* for dementia and death 
without dementia for current and former smokers vs. never smokers. Accounting for the 
competing risk of death in the Fine-Gray model mitigates the association between former 
smoking and dementia observed in the standard Cox model, and reveals a strong association 
between current smoking and incidence of mortality. Inclusion of milder forms of cognitive 
impairment further supports these results. 
 Cox Model Fine-Gray Models 
 
 Dementia Dementia   Death w/o Dementia 
Current smoker 1.20 0.50, 2.87 0.70  0.30, 1.64 2.38  1.52, 3.72 
Former smoker  1.64  1.09, 2.46 1.21  0.81, 1.80 1.15  0.87, 1.53 
 
 MCI/Dementia MCI/Dementia   
Death w/o 
MCI/Dementia 
Current smoker 0.80 0.39, 1.61 0.51 0.26, 0.99 2.52 1.63, 3.89 
Former smoker  1.33 0.96, 1.83 0.97 0.70, 1.34 1.16 0.87, 1.56 
*All hazard ratios are adjusted for baseline age, education, sex, APOE, hypertension, diabetes, 
head injury, hormone replacement therapy use, overweight, and family history of dementia.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
23 
 
Table 3: Adjusted odds ratios* between smoking status (ever vs. never) and 
neuropathological features among autopsied BRAiNS participants (N=302). Smoking 
history was associated with generally lower burden of both degenerative and 
cerebrovascular pathologies. 
Neuropathological feature 
Never 
Smoker 
(N=141) 
Ever 
Smoker 
(N=161) 
OR (95% CI) 
ADNC rating:  
    Intermediate/High AD        46.5 33.3 0.63 (0.38, 1.03) 
Neuritic Plaques:     
    Moderate/Severe 57.6 48.2 0.74 (0.45, 1.20) 
Diffuse Plaques:   
    Moderate/Severe 70.8 63.6 0.76 (0.45, 1.28) 
Braak neurofibrillary tangle   
    stage: V/VI  28.7 16.8 0.59 (0.33, 1.07) 
Diffuse Lewy body disease 9.0 6.2 0.66 (0.27, 1.63) 
Hippocampal Sclerosis of 
Aging 16.8 11.1 0.86 (0.42, 1.77) 
Cerebral amyloid angiopathy: 
    Moderate/Severe 21.1 20.4 1.08 (0.59, 1.98) 
Arteriolosclerosis:  
    Moderate/Severe 27.6 15.9 0.60 (0.31, 1.13) 
Atherosclerosis:  
    All vessels > 50% occluded 62.0 44.0 0.55 (0.33, 0.91) 
Hemorrhages present  8.3 7.4 0.84 (0.35, 2.04) 
Infarctions:      
   Micro-infarct present 40.3 40.7 0.96 (0.59, 1.55) 
   Lacunar infarct present 14.6 17.9 1.28 (0.67, 2.44) 
   Pale infarct present 27.1 14.8 0.49 (0.27, 0.90) 
   Macro-infarct present 27.1 13.6 0.41 (0.22, 0.75) 
*Odds ratios were adjusted for age at death, sex, and APOE carrier status. Braak score missing for 1 
smoker and 1 non-smoker. Amyloid angiopathy missing for 2 non-smokers. Hippocampal Sclerosis 
missing for 4 non-smokers. Arteriolosclerosis missing for 24 smokers and 21 non-smokers. 
Atherosclerosis missing for 3 smokers and 2 nonsmokers. 
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Figure 1: Cumulative incidence curves by baseline smoking status for the competing 
events death without dementia (Panel A) and dementia (Panel B). The predicted curves 
are based on hypothetical female participants who are 73 years old at baseline, with 
high education, no APOE-ε4, no family history of dementia, hypertension, no diabetes, 
no HRT use, normal weight, and no head injury. 
 
  
 
 

